1918 Influenza: the Mother of All Pandemics, Emerging Infectious Diseases, vol.12, issue.1, pp.15-22, 1918. ,
DOI : 10.3201/eid1209.05-0979
Influenza: Options to Improve Pandemic Preparation, Science, vol.336, issue.6088, pp.1531-1533, 2012. ,
DOI : 10.1126/science.1221466
Influenza Vaccines for the Future, New England Journal of Medicine, vol.363, issue.21, pp.2036-2044, 2010. ,
DOI : 10.1056/NEJMra1002842
The Systemic and Mucosal Immune Response of Humans to Influenza A Virus, Curr Top Microbiol Immunol, vol.146, pp.107-116, 1989. ,
DOI : 10.1007/978-3-642-74529-4_12
Randomized clinical trial of immunogenicity and safety of a recombinant H1N1/2009 pandemic influenza vaccine containing Advax??? polysaccharide adjuvant, Vaccine, vol.30, issue.36, pp.5407-5416, 2012. ,
DOI : 10.1016/j.vaccine.2012.06.009
Recombinant H1N1 virus-like particle vaccine elicits protective immunity in ferrets against the 2009 pandemic H1N1 influenza virus, Vaccine, vol.28, issue.30, pp.4771-4776, 2010. ,
DOI : 10.1016/j.vaccine.2010.04.093
Immunogenicity and Efficacy of Flagellin-Fused Vaccine Candidates Targeting 2009 Pandemic H1N1 Influenza in Mice, PLoS ONE, vol.27, issue.Pt 9, 2011. ,
DOI : 10.1371/journal.pone.0020928.t002
Formulation development of a plant-derived h1n1 influenza vaccine containing purified recombinant hemagglutinin antigen, Human Vaccines & Immunotherapeutics, vol.256, issue.4, 2012. ,
DOI : 10.1016/j.vaccine.2008.03.045
Induction of Broadly Neutralizing H1N1 Influenza Antibodies by Vaccination, Science, vol.329, issue.5995, pp.1060-1064, 2010. ,
DOI : 10.1126/science.1192517
Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection, Nature Biotechnology, vol.123, issue.12, 2012. ,
DOI : 10.1099/vir.0.014480-0
Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans, Nature Medicine, vol.94, issue.2, pp.274-280, 2012. ,
DOI : 10.1128/JVI.79.9.5684-5694.2005
T Cell Responses Are Better Correlates of Vaccine Protection in the Elderly, The Journal of Immunology, vol.176, issue.10, pp.6333-6339, 2006. ,
DOI : 10.4049/jimmunol.176.10.6333
The unmet need in the elderly: Designing new influenza vaccines for older adults, Vaccine, vol.23, issue.1, pp.10-25, 2005. ,
DOI : 10.1016/j.vaccine.2005.04.019
Neonatal Administration of IL-12 Enhances the Protective Efficacy of Antiviral Vaccines, The Journal of Immunology, vol.164, issue.7, pp.3698-3704, 2000. ,
DOI : 10.4049/jimmunol.164.7.3698
Distinct Contributions of Vaccine-Induced Immunoglobulin G1 (IgG1) and IgG2a Antibodies to Protective Immunity against Influenza, Clinical and Vaccine Immunology, vol.13, issue.9, pp.981-990, 2006. ,
DOI : 10.1128/CVI.00156-06
A pulmonary influenza virus infection in SCID mice can be cured by treatment with hemagglutinin-specific antibodies that display very low virusneutralizing activity in vitro, J Virol, vol.71, pp.4347-4355, 1997. ,
A VLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in mice, Virology Journal, vol.7, issue.1, pp.146-156, 2010. ,
DOI : 10.1186/1743-422X-7-146
A Virus-Like Particle-Based Vaccine Selectively Targeting Soluble TNF-?? Protects from Arthritis without Inducing Reactivation of Latent Tuberculosis, The Journal of Immunology, vol.178, issue.11, pp.7450-7457, 2007. ,
DOI : 10.4049/jimmunol.178.11.7450
Active immunization with IL-1 displayed on virus-like particles protects from autoimmune arthritis, European Journal of Immunology, vol.32, issue.3, pp.877-887, 2008. ,
DOI : 10.1002/eji.200737989
Protection against Osteoporosis by Active Immunization with TRANCE/RANKL Displayed on Virus-Like Particles, The Journal of Immunology, vol.175, issue.9, pp.6211-6218, 2005. ,
DOI : 10.4049/jimmunol.175.9.6211
Vaccination against IL-17 suppresses autoimmune arthritis and encephalomyelitis, European Journal of Immunology, vol.482, issue.11, pp.2857-2867, 2006. ,
DOI : 10.1002/eji.200636658
Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns, Nature Reviews Immunology, vol.54, issue.11, pp.787-796, 2010. ,
DOI : 10.1038/nri2868
Toll-dependent selection of microbial antigens for presentation by dendritic cells, Nature, vol.80, issue.7085, pp.808-812, 2006. ,
DOI : 10.1038/nature04596
A simple method of estimating fifty per cent endpoints, American Journal of Epidemiology, 1938. ,
Severe seasonal influenza in ferrets correlates with reduced interferon and increased IL-6 induction, Virology, vol.376, issue.1, pp.53-59, 2008. ,
DOI : 10.1016/j.virol.2008.02.035
Dendritic Cells Loaded With Killed Allogeneic Melanoma Cells can Induce Objective Clinical Responses and MART-1 Specific CD8+ T-cell Immunity, Journal of Immunotherapy, vol.29, issue.5, pp.545-557, 2006. ,
DOI : 10.1097/01.cji.0000211309.90621.8b
Circulating tumor antigen-specific regulatory T cells in patients with metastatic melanoma, Proceedings of the National Academy of Sciences, vol.104, issue.52, pp.20884-20889, 2007. ,
DOI : 10.1073/pnas.0710557105
Emergence of a Broad Repertoire of GAD65-Specific T-Cells in Type 1 Diabetes Patients With Graft Dysfunction After Allogeneic Islet Transplantation, Cell Transplantation, vol.21, issue.12, 2012. ,
DOI : 10.3727/096368912X654993
TLR9 Signaling in B Cells Determines Class Switch Recombination to IgG2a, The Journal of Immunology, vol.178, issue.4, pp.2415-2420, 2007. ,
DOI : 10.4049/jimmunol.178.4.2415
Universal vaccine against influenza virus: Linking TLR signaling to anti-viral protection, European Journal of Immunology, vol.40, issue.S4, pp.863-869, 2012. ,
DOI : 10.1002/eji.201041225
Innate Immunity Mediates Follicular Transport of Particulate but Not Soluble Protein Antigen, The Journal of Immunology, vol.188, issue.8, pp.3724-3733, 2012. ,
DOI : 10.4049/jimmunol.1103312
Innate signaling regulates cross-priming at the level of DC licensing and not antigen presentation, European Journal of Immunology, vol.183, issue.1, pp.103-112, 2010. ,
DOI : 10.1002/eji.200939559
Intranasal Vaccination with 1918 Influenza Virus-Like Particles Protects Mice and Ferrets from Lethal 1918 and H5N1 Influenza Virus Challenge, Journal of Virology, vol.83, issue.11, pp.5726-5734, 2009. ,
DOI : 10.1128/JVI.00207-09
Pandemic H1N1 vaccine requires the use of an adjuvant to protect against challenge in na??ve ferrets, Vaccine, vol.29, issue.11, pp.2120-2126, 2011. ,
DOI : 10.1016/j.vaccine.2010.12.125
New technologies for new influenza vaccines, Vaccine, vol.30, issue.33, pp.4927-4933, 2012. ,
DOI : 10.1016/j.vaccine.2012.04.095
The influence of antigen organization on B cell responsiveness, Science, vol.262, issue.5138, pp.1448-1451, 1993. ,
DOI : 10.1126/science.8248784
Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies, Journal of Clinical Investigation, vol.108, issue.3, pp.415-423, 2001. ,
DOI : 10.1172/JCI11849
Regulation of IgG antibody responses by epitope density and CD21-mediated costimulation, AID-IMMU3305.3.0.CO, pp.3305-3314, 2002. ,
DOI : 10.1002/1521-4141(200211)32:11<3305::AID-IMMU3305>3.0.CO;2-J
Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study, The Lancet, vol.371, issue.9615, pp.821-827, 2008. ,
DOI : 10.1016/S0140-6736(08)60381-5
A therapeutic vaccine for nicotine dependence: preclinical efficacy, and phase I safety and immunogenicity, European Journal of Immunology, vol.143, issue.7, pp.2031-2040, 2005. ,
DOI : 10.1002/eji.200526285
A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity, Journal of Hypertension, vol.25, issue.1, pp.63-72, 2007. ,
DOI : 10.1097/HJH.0b013e32800ff5d6
A Vaccine against Nicotine for Smoking Cessation: A Randomized Controlled Trial, PLoS ONE, vol.3, issue.6, 2008. ,
DOI : 10.1371/journal.pone.0002547.s002
Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults, Journal of Allergy and Clinical Immunology, vol.117, issue.6, pp.1470-1476, 2006. ,
DOI : 10.1016/j.jaci.2006.01.040
Safety, tolerability, and antibody response of active Ab immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebocontrolled , first-in-human study, Lancet Neurol, vol.1112, pp.597-604, 2012. ,
Antigenic Drift of the Pandemic 2009 A(H1N1) Influenza Virus in a Ferret Model, PLoS Pathogens, vol.91, issue.5, 2013. ,
DOI : 10.1371/journal.ppat.1003354.s004
Memory CD4 T Cells Direct Protective Responses to Influenza Virus in the Lungs through Helper-Independent Mechanisms, Journal of Virology, vol.84, issue.18, pp.9217-9226, 2010. ,
DOI : 10.1128/JVI.01069-10
Memory CD4+ T cells protect against influenza through multiple synergizing mechanisms, Journal of Clinical Investigation, vol.122, issue.8, pp.2847-2856, 2012. ,
DOI : 10.1172/JCI63689DS1
Tumor Necrosis Factor Alpha Exerts Powerful Anti-Influenza Virus Effects in Lung Epithelial Cells, Journal of Virology, vol.76, issue.3, pp.1071-1076, 2002. ,
DOI : 10.1128/JVI.76.3.1071-1076.2002
The Immunoglobulin G Subclass Responses of Mice to Influenza A Virus: the Effect of Mouse Strain, and the Neutralizing Abilities of Individual Protein A-purified Subclass Antibodies, Journal of General Virology, vol.70, issue.9, pp.2439-2448, 1989. ,
DOI : 10.1099/0022-1317-70-9-2439
Immunization with Reverse???Genetics???Produced H5N1 Influenza Vaccine Protects Ferrets against Homologous and Heterologous Challenge, The Journal of Infectious Diseases, vol.194, issue.2, pp.159-167, 2006. ,
DOI : 10.1086/505225
Efficacy of a heterologous vaccine and adjuvant in ferrets challenged with influenza virus H5N1, Influenza and Other Respiratory Viruses, vol.6, issue.5, 2012. ,
DOI : 10.1111/j.1750-2659.2011.00321.x
Lack of adjuvant effect of A1PO4 on purified influenza virus hemagglutinins in man, J Immunol, vol.100, pp.1139-1140, 1968. ,
Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial, The Lancet, vol.367, issue.9523, pp.1657-1664, 1194. ,
DOI : 10.1016/S0140-6736(06)68656-X
Chapter 51: Influenza. New Generation Vaccines, 2009. ,